Alector, Inc. financial data

Symbol
ALEC on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
131 Oyster Point Blvd., Suite 600, South San Francisco, CA
Fiscal year end
December 31
Former names
Alector LLC (to 9/16/2015)
Latest financial report
10-K - Q4 2024 - Feb 26, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 344 % -22.7%
Debt-to-equity 281 % -8.52%
Return On Equity -82.8 % -7.31%
Return On Assets -21.7 % -14.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 99.1M shares +2.8%
Common Stock, Shares, Outstanding 99.1M shares +16.7%
Entity Public Float 311M USD -18.9%
Common Stock, Value, Issued 9K USD +12.5%
Weighted Average Number of Shares Outstanding, Basic 96.6M shares +15.4%
Weighted Average Number of Shares Outstanding, Diluted 96.6M shares +15.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 101M USD +3.6%
Research and Development Expense 186M USD -3.21%
General and Administrative Expense 59.6M USD +5.17%
Operating Income (Loss) -145M USD +4.44%
Income Tax Expense (Benefit) 128K USD -97.5%
Net Income (Loss) Attributable to Parent -119M USD +8.7%
Earnings Per Share, Basic -1.23 USD/shares +21.2%
Earnings Per Share, Diluted -1.23 USD/shares +21.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 33M USD -55.7%
Marketable Securities, Current 380M USD -19.8%
Assets, Current 425M USD -24.9%
Property, Plant and Equipment, Net 17.1M USD -21.6%
Operating Lease, Right-of-Use Asset 20M USD -20.8%
Other Assets, Noncurrent 4.54M USD -38.7%
Assets 468M USD -24.7%
Accounts Payable, Current 2.22M USD -41.3%
Employee-related Liabilities, Current 18.2M USD +19.1%
Accrued Liabilities, Current 28.9M USD -4.9%
Contract with Customer, Liability, Current 23.7M USD -71.5%
Liabilities, Current 125M USD -29.7%
Contract with Customer, Liability, Noncurrent 172M USD -18.3%
Operating Lease, Liability, Noncurrent 24.4M USD -20%
Other Liabilities, Noncurrent 1.23M USD -10.1%
Liabilities 342M USD -30%
Accumulated Other Comprehensive Income (Loss), Net of Tax 261K USD +41.8%
Retained Earnings (Accumulated Deficit) -829M USD -16.8%
Stockholders' Equity Attributable to Parent 127M USD -5.49%
Liabilities and Equity 468M USD -24.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -61.3M USD -26.4%
Net Cash Provided by (Used in) Financing Activities 71.1M USD +6490%
Net Cash Provided by (Used in) Investing Activities -11.8M USD -113%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 99.1M shares +16.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2M USD -105%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 34.9M USD -54.2%
Deferred Tax Assets, Valuation Allowance 231M USD +13.1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 240M USD +11.5%
Operating Lease, Liability 33.1M USD -14.9%
Payments to Acquire Property, Plant, and Equipment 533K USD -48%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -119M USD +5.3%
Lessee, Operating Lease, Liability, to be Paid 39.6M USD -18.3%
Property, Plant and Equipment, Gross 50.1M USD +0.35%
Operating Lease, Liability, Current 8.75M USD +3.45%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.48M USD +3.45%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.16M USD +3.46%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.49M USD -32.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.8M USD +3.45%
Deferred Tax Assets, Operating Loss Carryforwards 36.8M USD +196%
Unrecognized Tax Benefits 22.9M USD +13.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.97M USD -8.52%
Additional Paid in Capital 956M USD +13.2%
Deferred Tax Assets, Net of Valuation Allowance 8.26M USD -20.5%
Share-based Payment Arrangement, Expense 39.5M USD -7.79%